Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2025 | Improving the understanding of the genetics and biology underlying Richter’s transformation

In this video, Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses recent studies aimed at deepening the understanding of the genetics and biology underlying Richter’s transformation. Dr Parry highlights that paired sequencing of samples from over 100 patients has revealed common patterns of clonal evolution that can inform the risk of transformation. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So there’s been a number of studies now. So now we have an aggregate across these different studies, more than 100 patients where there have been sort of paired sequencing of CLL, Richter samples, and normal samples. So now we’re able to understand some of the common patterns of clonal evolution that sort of can get you towards that end result of transformation...

So there’s been a number of studies now. So now we have an aggregate across these different studies, more than 100 patients where there have been sort of paired sequencing of CLL, Richter samples, and normal samples. So now we’re able to understand some of the common patterns of clonal evolution that sort of can get you towards that end result of transformation. And obviously not everyone that may have some of the genetic risk factors ends up getting transformation. That’s still only a small subset of patients but we’re being able to understand some of the different genetic patterns that we see as well as some of the different pathways that are just regulated between CLL and Richter cells.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

 

Read more...